Beam Therapeutics (BEAM) Following Ark Invest Interest And Clinical Milestones Looks Undervalued

Beam Therapeutics (BEAM) is back in focus after Ark Invest increased its position, as investors weigh upcoming clinical milestones, including a global BEAM-302 trial and a planned FDA marketing application for risto-cel.

See our latest analysis for Beam Therapeutics.

Despite Ark Invest’s increased stake and Beam Therapeutics’ upcoming clinical milestones, recent momentum has been weak, with the share price down 25.0% over 30 days and the 1-year total shareholder return still positive at 20.2%, in contrast with deeper 3 and 5-year total return declines.

If Beam’s recent pullback has you reassessing biotech risk, it may help to compare it with other precision-medicine opportunities using our screener of 41 healthcare AI stocks.

Beam Therapeutics now trades at a steep discount to the average analyst price target after a sharp pullback, yet the company still carries clinical and earnings risk. Is the market being cautious, or excessively cautious as the valuation section shows?

Most Popular Narrative: 47.8% Undervalued

With Beam Therapeutics last closing at $26.64 against a narrative fair value of $51.07, the most followed narrative sees a large gap between price and expectations, anchored in its gene editing pipeline.

The development of ESCAPE technology aims to expand the addressable patient population for gene editing by eliminating chemotherapy, which could significantly increase the market and, subsequently, revenue and margins.
Beam has nominated BEAM-103 and BEAM-104 for their ESCAPE program, which could bring transformative changes in transplant medicine by enabling non-genotoxic conditioning, leading to broader patient access and a potential increase in revenue.

Read the complete narrative.

Curious what kind of revenue ramp and margin shift would need to line up with those ESCAPE ambitions? The narrative leans on aggressive growth, higher profitability and a rich future earnings multiple, all working together to support that $51.07 fair value.

Result: Fair Value of $51.07 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Beam Therapeutics narrative still hinges on managing busulfan safety concerns and securing ongoing funding. Any setback here could quickly erode those valuation assumptions.

Find out about the key risks to this Beam Therapeutics narrative.

Another View: Beam Therapeutics Through the P/S Lens

The analyst narrative pegs Beam Therapeutics as undervalued against a $51.07 fair value, but the revenue multiple tells a tougher story. The stock trades on a P/S of 16.2x, richer than the US Biotechs industry at 11x and far above a fair ratio of 1.2x, even if it is lower than a 35.1x peer average. That kind of gap points to meaningful valuation risk if expectations reset, so how comfortable are you with paying this premium for Beam’s pipeline?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With Beam Therapeutics pulled between optimism on its pipeline and concern about valuation and clinical risk, it makes sense to check the numbers yourself instead of relying on a single story. To see where the balance of risks and rewards currently sits for Beam, take a look at the 2 key rewards and 2 important warning signs.

Looking for more ideas beyond Beam Therapeutics?

If you want to round out your view beyond Beam Therapeutics, use the Simply Wall St Screener to quickly surface fresh stock ideas that match your risk and return preferences.

• Target potential mispricings by running through our list of 47 high quality undervalued stocks that combine attractive pricing with solid underlying metrics.
• Strengthen your income stream by reviewing 7 dividend fortresses built around companies offering higher yields with staying power.
• Sleep easier at night by checking out 82 resilient stocks with low risk scores that focus on businesses with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com